Acadia Pharmaceuticals | ACAD - Ebitda


Acadia Pharmaceuticals reported $-1.62M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD -49M 53.2M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Eisai JPY 34.15B 34.48B Jun/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
J&J USD 8.27B 1.08B Mar/2026
Moderna USD -1.26B 468M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Prothena USD 25.98M 65.51M Mar/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026